Showing 6581-6590 of 8826 results for "".
- AAD Releases New Melanoma Guidelineshttps://practicaldermatology.com/news/aad-releases-new-melanoma-guidelines/2457522/As National Healthy Skin Month begins, the American Academy of Dermatology’s (AAD) new melanoma guidelines shed light on risk of melanoma prognosis during pregnancy, the role of formal genetic testing in at-risk families and other aspects of care for primary cutaneous melanoma.
- Ortho Dermatologics' Altreno Now Available in the UShttps://practicaldermatology.com/news/ortho-dermatologics-altreno-now-available-in-the-us/2457526/Ortho Dermatologics launched Altreno (tretinoin) Lotion, 0.05% for the topical treatment of acne vulgaris in patients 9 years of age and older. Altreno Lotion is the first and only tretinoin available in a lotion for acne. Altreno Lotion has been shown to be effective and generally well-tolerated
- Pennsylvania Passes SUNucate, Allowing Sunscreen Use and Protective Clothing at Schoolhttps://practicaldermatology.com/news/pennsylvania-passes-sunucate-allowing-sunscreen-use-and-protective-clothing-at-school/2457529/Pennsylvania became the 17th state to allow children to possess and apply sunscreen at school. Governor Tom Wolf approved HB 1228, a piece of legislation based on American Society for Dermatologic Surgery Association’s (ASDA) model bill known as SUNucate<
- New from xMedica: Aesthetics Conference Features Energy Based Treatments for Male and Female Sexual Wellnesshttps://practicaldermatology.com/news/new-from-xmedica-aesthetics-conference-features-energy-based-treatments-for-male-and-female-sexual-wellness/2457553/Medical education consortium xMedica LLC of Atlanta has developed a new educational initiative, "The Use of Energy-Based Devices for Improving Sexual Health." The overriding goal of this unique conference is to present factual data in a CME setting to address this new are
- Aclaris Acquires Rhofade from Allerganhttps://practicaldermatology.com/news/aclaris-acquires-rhofade-from-allergan/2457561/Aclaris Therapeutics, Inc. has entered into a definitive asset purchase agreement with Allergan Sales, LLC to acquire worldwide rights to Rhofade® (oxymetazoline hydrochloride) cream, 1% and additional intellectual property. The acquisition includes an exclusive license to certain intel
- Music City SCALE: Registration Open; New Website Launcheshttps://practicaldermatology.com/news/music-city-scale-registration-open-new-website-launches/2457564/Registration is now open for Music City Scale on the meeting's newly redesigned website. The website features new details about the meeting, scheduled May 9-11, 2019
- ASDS Announces 2018 President's Award Recipientshttps://practicaldermatology.com/news/asds-announces-2018-presidents-award-recipients/2457565/In her final act as president this week, Lisa M. Donofrio, MD, recognizes four members of the American Society for Dermatologic Surgery (ASDS) with the President’s Award at the Society’s Annual Meeting. “One of the wonderful gifts about being president of an organization
- Cellulite Reduction Seen With Cellfina Lasts Five Yearshttps://practicaldermatology.com/news/cellulite-reduction-seen-with-cellfina-lasts-five-years/2457566/One Cellfina treatment improves the appearance of cellulite on the thighs and buttocks for five years, according to new data presented by Merz at the Annual Meeting of the American Society for Dermatologic Surgery (ASDS) in Phoenix, AZ. This new data b
- Alastin Skincare's Latest Product May Become Body Contouring Procedures' New BFFhttps://practicaldermatology.com/news/alastin-skincares-latest-product-may-be-body-contouring-procedures-new-bff/2457573/
- Ortho Dermatologics Receives Tentative FDA Approval for Bryhali for Plaque Psoriasishttps://practicaldermatology.com/news/ortho-dermatologics-received-tentative-fda-approval-for-bryhali-for-plaque-psoriasis/2457575/The FDA has provided tentative approval of the New Drug Application for Bryhali (halobetasol propionate) Lotion, 0.01%, for the topical treatment of plaque psoriasis in adult patients. Bryhali Lotion is a new potent to superpotent corticosteroid that contains 0.01 percent halobetasol propionate i